Enzamin improves adipose tissue inflammation with impaired adipocytokine expression and insulin resistance in obese mice (688.1)

<jats:p>Aim: Effects of Enzamin, which is a product from Bacillus subtilis AK and Lactobacillus, on obesity‐related metabolic disorders in obese db/db mice were examined to explore a novel agent for the prevention of insulin resistance.</jats:p><jats:p>Methods and Results: Db/db mice were treated with water containing Enzamin (0.1% and 1.0%) for 8 weeks from 6 weeks of age. Enzamin treatment at 1.0% significantly decreased the fasting plasma glucose, serum total cholesterol and triglyceride levels in db/db mice. Furthermore, insulin resistance was improved by the treatment of db/db mice with Enzamin. Enzamin suppressed macrophage accumulation and inflammation in the adipose tissue and increased serum adiponectin in db/db mice. Enzamin also significantly suppressed the expression of NADPH oxidase subunits, suggesting an anti‐oxidative effect of Enzamin in the adipose tissue. Enzamin increased the mRNA expression of GLUT4 and carnitine palmitoyltransferase 1a in muscle of db/db mice. Further, in vitro experiments demonstrated that the lipopolysaccharide‐induced inflammatory reaction was significantly suppressed by Enzamin in macrophages.</jats:p><jats:p>Conclusion: Our data indicates that Enzamin can improve insulin resistance by ameliorating impaired adipocytokine expression, presumably through its anti‐inflammatory action, and that Enzamin possesses a potential for preventing metabolic syndrome.</jats:p><jats:p><jats:bold><jats:italic>Grant Funding Source</jats:italic></jats:bold><jats:italic>: None</jats:italic></jats:p>